Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
2020 · Journal for ImmunoTherapy of Cancer · 173 citations
https://doi.org/10.1136/jitc-2020-000696
J
Jieqiong Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
114
Papers
2.4K
Citations
27
h-index
52
i10-index
Jieqiong Liu is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies. The author has an h-index of 27, co-authored 97 publications.
ORCID: 0000-0001-7859-3764Papers by this author
worksMulticenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
2022 · Nature Communications · 96 citations
https://doi.org/10.1038/s41467-022-30569-0
Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database
2016 · Journal of Cancer Research and Clinical Oncology · 52 citations
https://doi.org/10.1007/s00432-016-2281-6
Development of nomograms to predict axillary lymph node status in breast cancer patients
2017 · BMC Cancer · 45 citations
https://doi.org/10.1186/s12885-017-3535-7
Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer
2019 · BMC Cancer · 30 citations
https://doi.org/10.1186/s12885-019-5703-4
Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment
2012 · Journal of Cancer Research and Clinical Oncology · 25 citations
https://doi.org/10.1007/s00432-012-1150-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat